Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy

Human Gene Therapy Methods

Volumn 23, Issue 1, 2012, Pages 38-55

  Pincha, Mudita ^a   Sai Sundarasetty, Bala ^a   Salguero, Gustavo ^a   Gutzmer, Ralf ^a   Garritsen, Henk ^b   MacKe, Laura ^a   Schneider, Andreas ^a   Lenz, Daniela ^b   Figueiredo, Constanca ^a   Blasczyk, Rainer ^a   Ruggiero, Eliana ^c   Schmidt, Manfred ^c   Von Kalle, Christof ^c   Puff, Christina ^d   Modlich, Ute ^e   Von Der Leyen, Heiko ^f   Wicke, Daniel C ^f   Ganser, Arnold ^a   Stripecke, Renata ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^e Department of Experimental Hematology ^*  (Germany)

^f Hannover Clinical Trial Center GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LENTIVIRUS VECTOR; MELANOMA ANTIGEN; TYROSINE RELATED PROTEIN 2; UNCLASSIFIED DRUG; 5 (6) CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; 5-(6)-CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CYTOKINE; FLUORESCEIN DERIVATIVE; IL2RG PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR GAMMA; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; PEPTIDE SVYDFFVWL; PRIMER DNA; SUCCINIMIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW CELL; C57BL 6 MOUSE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL SEPARATION; CELL VIABILITY; CISTRON; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE RELEASE; DENDRITIC CELL; GENETIC TRANSDUCTION; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; MELANOMA; MONOCYTE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; RISK ASSESSMENT; SCALE UP; SELF DIFFERENTIATED MYELOID DERIVED ANTIGEN PRESENTING CELLS REACTIVE AGAINST TUMORS; STANDARDIZATION; THAWING; ANIMAL; BIOTECHNOLOGY; CELL LINE; FLOW CYTOMETRY; GENE; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LENTIVIRINAE; METHODOLOGY; MOUSE MUTANT; SECRETION (PROCESS); VIROLOGY; WESTERN BLOTTING;

ANIMALS; BIOTECHNOLOGY; BLOTTING, WESTERN; CELL LINE; CRYOPRESERVATION; CYTOKINES; DENDRITIC CELLS; DNA PRIMERS; FLOW CYTOMETRY; FLUORESCEINS; GENES, RAG-1; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LENTIVIRUS; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; SUCCINIMIDES;

EID: 84863783322     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2011.170     Document Type: Article

References (44)

1. Avogadri, F., Merghoub, T., Maughan, M.F., et al. (2010). Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 5.
2. Babatz, J., Rollig, C., Oelschlagel, U., et al. (2003). Large-scale immunomagnetic selection of CD14 + monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J. Hematother. Stem Cell Res. 12, 515-523. (Pubitemid 37305564)
3. Berger, T.G., Feuerstein, B., Strasser, E., et al. (2002). Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J. Immunol. Methods 268, 131-140. (Pubitemid 35246159)
4. Boasberg, P.D., Hoon, D.S., Piro, L.D., et al. (2006). Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J. Invest. Dermatol. 126, 2658-2663. (Pubitemid 44764050)
5. Breckpot, K., Heirman, C., De Greef, C., et al. (2004). Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J. Immunol. 172, 2232-2237. (Pubitemid 38182371)
6. Bridle, B.W., Li, J., Jiang, S., et al. (2010). Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen. J. Immunol. 184, 4269-4275.
7. Cassady, J.L., and Sturm R.A. (1994). Sequence of the human dopachrome tautomerase-encoding TRP-2 cDNA. Gene 143, 295-28.
8. Chapman, P.B., Hauschild, A., Robert, C., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
9. Cornetta, K., Yao, J., Jasti, A., et al. (2011). Replication-competent lentivirus analysis of clinical grade vector products. Mol. Ther. 19, 557-566.
10. Dietz, A.B., Padley, D.J., Butler, G.W., et al. (2004). Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy 6, 563-570. (Pubitemid 40028915)
11. Dull, T., Zufferey, R., Kelly, M., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471. (Pubitemid 28471781)
12. Dullaers, M., Breckpot, K., Van Meirvenne, S., et al. (2004). Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol. Ther. 10, 768-779. (Pubitemid 39272866)
13. Engell-Noerregaard, L., Hansen, T.H., Andersen, M.H., et al. (2009). Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol. Immunother. 58, 1-14.
14. Esche, C., Shurin, G.V., Kirkwood, J.M., et al. (2001). Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin. Cancer Res. 7, 974s-979s. (Pubitemid 33600953)
15. Figdor, C.G., De Vries, I.J., Lesterhuis, W.J., and Melief CJ. (2004). Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480. (Pubitemid 38667904)
16. Giblin, A.V., and Thomas, J.M. (2007). Incidence, mortality and survival in cutaneous melanoma. J. Plast. Reconstr. Aesthet. Surg. 60, 32-40. (Pubitemid 44763123)
17. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
18. Jirmo, A.C., Koya, R.C., Sundarasetty, B.S., et al. (2010). Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8( + ) T cell responses. Vaccine 28, 922-933.
19. Khong, H.T., and Rosenberg, S.A. (2002). Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J. Immunol. 168, 951-956. (Pubitemid 34049600)
20. Kimura, T., Koya, R.C., Anselmi, L., et al. (2007). Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol. Ther. 15, 1390-1399. (Pubitemid 46965335)
21. Koya, R.C., Kimura, T., Ribas, A., et al. (2007). Lentiviral vectormediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol. Ther. 15, 971-980. (Pubitemid 46621656)
22. Lee, M.L., Tomsu, K., and Von Eschen, K.B. (2000). Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res. 10, 81-92. (Pubitemid 30127833)
23. Lizee, G., Gonzales, M.I., and Topalian, S.L. (2004). Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gene Ther. 15, 393-404. (Pubitemid 38469781)
24. Lopes, L., Fletcher, K., Ikeda, Y., and Collins, M. (2006). Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol. Immunother. 55, 1011-1016. (Pubitemid 43673592)
25. Michiels, A., Tuyaerts, S., Bonehill, A., et al. (2005). Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther. 12, 772-782. (Pubitemid 40668416)
26. Motta, M.R., Castellani, S., Rizzi, S., et al. (2003). Generation of dendritic cells from CD14 + monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br. J. Haematol. 121, 240-250. (Pubitemid 36560590)
27. Pak, B.J., Lee, J., Thai, B.L., et al. (2004). Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene 23, 30-38. (Pubitemid 38142237)
28. Parkhurst, M.R., Fitzgerald, E.B., Southwood, S., et al. (1998). Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58, 4895-4901. (Pubitemid 28503687)
29. Paschen, A., Song, M., Osen, W., et al. (2005). Detection of spontaneous CD4 + T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLADRB1* 0301 transgenic mice. Clin. Cancer Res. 11, 5241-5247. (Pubitemid 41003712)
30. Pincha, M., Salguero, G., Wedekind, D., et al. (2011). Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells. Gene Ther. 18, 750-764.
31. Quah, B.J., Warren, H.S., Parish, C.R. (2007). Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2, 2049-2056. (Pubitemid 351565842)
32. Ribas, A. (2005). Genetically modified dendritic cells for cancer immunotherapy. Curr. Gene Ther. 5, 619-628. (Pubitemid 43009506)
33. Salguero, G., Sundarasetty, B.S., Borchers, S., et al. (2011). Preconditioning therapy with lentiviral vector-programmed dendritic cells accelerates the homeostatic expansion of antigen-reactive human T cells in NOD.Rag1-/-.IL-2rcc-/-mice. Hum. Gene Ther. 22, 1209-1224.
34. Satzger, I., Kuttler, U., Volker, B., et al. (2010). Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy-case report and review of the literature. Dermatology 220, 77-81.
35. Schambach, A., Bohne, J., Baum, C., et al. (2006). Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther. 13, 641-645.
36. Shibagaki, N., and Udey, M.C. (2003). Dendritic cells transduced with TAT protein transduction domain-containing tyrosinaserelated protein 2 vaccinate against murine melanoma. Eur. J. Immunol. 33, 850-860. (Pubitemid 36546672)
37. Sims, R.B. (2011). Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. J. Cancer 2, 357-359.
38. Stripecke, R. (2009). Lentiviral vector-mediated genetic programming of mouse and human dendritic cells. Methods Mol. Biol. 506, 139-158.
39. Szymczak, A.L., and Vignali, D.A. (2005). Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin. Biol. Ther. 5, 627-638. (Pubitemid 40780547)
40. Voigtlander, C., Rossner, S., Cierpka, E., et al. (2006). Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity. J. Immunother. 29, 407-415. (Pubitemid 44288953)
41. Wang, R.F., and Wang, H.Y. (2002). Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol. 20, 149-154. (Pubitemid 34158030)
42. Wang, T., Dai, H., Wan, N., et al. (2008). The role for monocyte chemoattractant protein-1 in the generation and function of memory CD8 + T cells. J. Immunol. 180, 2886-2893.
43. Wilson, C.A., and Cichutek, K. (2009). The Us and Eu regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors. Methods Mol. Biol. 506, 477-488.
44. Zufferey, R., Dull, T., Mandel, R.J., et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880. (Pubitemid 28520853)